Details for Patent: 9,271,968
✉ Email this page to a colleague
Which drugs does patent 9,271,968 protect, and when does it expire?
Patent 9,271,968 protects XIFAXAN and is included in one NDA.
This patent has thirty-four patent family members in twenty-six countries.
Summary for Patent: 9,271,968
| Title: | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
| Abstract: | Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin .delta. and rifaximin .epsilon. useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. |
| Inventor(s): | Viscomi; Giuseppe Claudio (Sasso Marconi, IT), Campana; Manuela (Bologna, IT), Confortini; Donatella (Calderara di Reno, IT), Barbanti; Maria (Bologna, IT), Braga; Dario (Bologna, IT) |
| Assignee: | ALFA WASSERMANN S.P.A. (IT) |
| Application Number: | 14/262,612 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,271,968 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 9,271,968
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 021361-001 | May 25, 2004 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 021361-002 | Mar 24, 2010 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,271,968
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2006222312 | ⤷ Try a Trial | |||
| Brazil | PI0608073 | ⤷ Try a Trial | |||
| Canada | 2594789 | ⤷ Try a Trial | |||
| China | 1900077 | ⤷ Try a Trial | |||
| Denmark | 1698630 | ⤷ Try a Trial | |||
| European Patent Office | 1698630 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
